CEO Today Magazine April 2019 Edition

69 www.ceotodaymagazine.com APPOINTMENTS Metropolitan Market (Southern Maryland, Washington D.C. and Northern Virginia); and Senior Financial Specialist in Northern Virginia. Nowland also spent two years during this timeframe as the Vice President of Sales & Marketing for NETSEC, an internet technology company funded by E-Trade, which was ultimately acquired by MCI for $105 million. Rob Mackay Appointed New CEO of Itiviti Itiviti, a leading technology and service provider to financial institutions worldwide, announced the appointment of Robert N. Mackay as the company’s new Chief Executive Officer. The Itiviti Board of Directors has carried out a thorough search process to find a new CEO. Rob Mackay was selected for the position by virtue of his experience as a successful industry executive with a strong track record and customer focus. Rob joins Itiviti from Fidelity National Information Services (FIS), the world’s largest provider of banking technology solutions. He brings decades of experience and most recently was Chief Operating Officer for the FIS Cross-Asset Trading & Risk business unit. His previous management experience includes positions as Chief Operating Officer of Hedge Funds & Risk and Managing Director of Alternative Investments. “We are very pleased to welcome Rob Mackay as the new CEO of Itiviti. Rob has a strong track record in creating value and driving growth in finance and trading industry businesses. We are confident that his excellent sales background and solid understanding of customer needs makes him the right leader to take Itiviti to the next level, as an innovative and supportive partner to our customers,” said Per E. Larsson, Chairman of the Board, Itiviti. RDD Pharma Appoints John Temperato as Chief Executive Officer RDD Pharma, Inc., a specialty pharmaceutical company focused on innovative therapies for anorectal diseases and gastrointestinal disorders, announced the appointment of industry veteran John Temperato as Chief Executive Officer. Prior to joining RDD, John held various leadership roles including most notably US President & Chief Operating Officer with Atlantic Healthcare, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Mr. Temperato brings a wealth of gastrointestinal (GI) focused experience in both the operational and commercial aspects of the business. Notably, at Salix Pharmaceuticals, Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving growth of company revenues from $119 million in 2004 to $2 billion in 2015. “John’s GI-focused background and strong track record of building businesses behind successful product launches, as well as his extensive involvement in business development transactions, fits perfectly with the plans we have to grow RDD into a significant GI franchise,” commented Dr. Mark A. Sirgo, Chairman of the Board of RDD. Across his career, John has been instrumental in defining and executing capital efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. He built and directed several new sales divisions and developed strategies for reimbursement and external healthcare policy. John also brings with him extensive financial strategy and investor relations experience. He holds a Bachelor of Science degree from the University of Bridgeport in Bridgeport, CT. Advancing Eyecare Announces Appointment of Brad Staley as Chief Executive Officer Advancing Eyecare, a newly-formed holding company owned by private equity firm Atlantic Street Capital, has announced the appointment of Brad Staley to the role of Chief Executive Officer. Mr. Staley will oversee all operations of Advancing Eyecare’s ophthalmic equipment industry leaders Lombart Instrument, Marco, INNOVA, and Enhanced Medical Services. Staley joins Advancing Eyecare with over 24 years of global operating experience in healthcare, technology, and manufacturing companies including most recently as CEO of United Scope, a private equity-owned global provider of microscopy and optical solutions. Prior to United Scope, he led vision care companies for more than a decade in the Americas, Europe, and Asia Pacific. Brad served as President of Signet Armorlite, a business unit of Essilor, and Chief Operating Officer of Performance Optics, a global ophthalmic lens manufacturer recently sold to HOYA Corporation. A graduate of the United States Naval Academy with a degree in physics, Staley also holds an MBA from Fuqua School of Business at Duke University and served as a naval officer on the USS Enterprise.